• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
REPH

REPH

Recro Pharma, Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD2.09

-0.01 (-0.48%)

Company Profile

CEO

Geraldine Henwood

IPO Date

2014-03-07

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$2.07

Prev. Close

$2.10

Day Low

$2.00

Day High

$2.14

52W Low

$1.38

52W High

$3.29

Market Cap

$0.18B

Volume

0.14M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

40.6%

Avg Negative

3.4%

Avg Neutral

56.0%

News Feed

Recro Appoints Laura L. Parks, Ph.D.

GlobeNewsWire·6/16/2021·↑ positive

Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewsWire·5/14/2021·↑ positive

Recro Announces Proposed Public Offering of Common Stock

GlobeNewsWire
·5/11/2021
·↑ positive

Recro Pharma, Inc. (REPH) CEO David Enloe on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/9/2021·↓ negative

Recro Reports First Quarter 2021 Financial Results

GlobeNewsWire·5/6/2021·↑ positive

Recro to Report Financial Results for First Quarter 2021 on May 6

GlobeNewsWire·4/29/2021·↓ negative

Recro Strengthens Business Development Team to Drive Customer Growth and Diversification

GlobeNewsWire·4/5/2021·↑ positive

Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·2/27/2021·↓ negative

Recro Reports Fourth Quarter and Year End 2020 Financial Results

GlobeNewsWire·2/26/2021·↑ positive

Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced

GlobeNewsWire·2/23/2021·↓ negative